Company intelligence / Profile preview

Leadartis

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Leadartis has developed a novel class of bispecific/multispecific Fc-less antibodies called Trimerbodies. Their lead compound LEAD‑452—a conditional agonist targeting both EGFR and the immune co-stimulatory receptor 4‑1BB—has demonstrated superior safety/pharmacokinetics in non-human primate studies with no adverse events. The company claims a greater therapeutic window compared to competitors’ formats. LEAD‑452 is ready for clinical manufacturing and first-in-human Phase I basket study across multiple advanced cancer indications.

Therapeutic areas: OncologyGastroenterology
Modalities: Bispecific antibodiesMultispecific antibodiesSingle-chain FV antibody fragments
Industry: Biotech

Drug pipeline

3 assets

LEAD-452

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Leadartis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leadartis.

Explore the full profile